These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21505303)

  • 1. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
    Métifiot M; Vandegraaff N; Maddali K; Naumova A; Zhang X; Rhodes D; Marchand C; Pommier Y
    AIDS; 2011 Jun; 25(9):1175-8. PubMed ID: 21505303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants.
    Marinello J; Marchand C; Mott BT; Bain A; Thomas CJ; Pommier Y
    Biochemistry; 2008 Sep; 47(36):9345-54. PubMed ID: 18702518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple genetic pathways involving amino acid position 143 of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir.
    Huang W; Frantzell A; Fransen S; Petropoulos CJ
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4105-13. PubMed ID: 23733474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo.
    Delelis O; Thierry S; Subra F; Simon F; Malet I; Alloui C; Sayon S; Calvez V; Deprez E; Marcelin AG; Tchertanov L; Mouscadet JF
    Antimicrob Agents Chemother; 2010 Jan; 54(1):491-501. PubMed ID: 19901095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.
    Malet I; Gimferrer Arriaga L; Artese A; Costa G; Parrotta L; Alcaro S; Delelis O; Tmeizeh A; Katlama C; Valantin MA; Ceccherini-Silberstein F; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2014 Aug; 69(8):2118-22. PubMed ID: 24710029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4.
    Margot NA; Hluhanich RM; Jones GS; Andreatta KN; Tsiang M; McColl DJ; White KL; Miller MD
    Antiviral Res; 2012 Feb; 93(2):288-296. PubMed ID: 22197635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.
    Smith RA; Raugi DN; Pan C; Coyne M; Hernandez A; Church B; Parker K; Mullins JI; Sow PS; Gottlieb GS;
    PLoS One; 2012; 7(9):e45372. PubMed ID: 23028968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.
    Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O
    J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unravelling the dynamics of selection of multiresistant variants to integrase inhibitors in an HIV-1-infected child using ultra-deep sequencing.
    Stefic K; Salmona M; Capitao M; Splittgerber M; Maakaroun-Vermesse Z; Néré ML; Bernard L; Chaix ML; Barin F; Delaugerre C
    J Antimicrob Chemother; 2017 Mar; 72(3):850-854. PubMed ID: 27999055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.
    Heger E; Theis AA; Remmel K; Walter H; Pironti A; Knops E; Di Cristanziano V; Jensen B; Esser S; Kaiser R; Lübke N
    J Virol Methods; 2016 Dec; 238():29-37. PubMed ID: 27737783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir.
    Métifiot M; Maddali K; Naumova A; Zhang X; Marchand C; Pommier Y
    Biochemistry; 2010 May; 49(17):3715-22. PubMed ID: 20334344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes.
    Hightower KE; Wang R; Deanda F; Johns BA; Weaver K; Shen Y; Tomberlin GH; Carter HL; Broderick T; Sigethy S; Seki T; Kobayashi M; Underwood MR
    Antimicrob Agents Chemother; 2011 Oct; 55(10):4552-9. PubMed ID: 21807982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dolutegravir interactions with HIV-1 integrase-DNA: structural rationale for drug resistance and dissociation kinetics.
    DeAnda F; Hightower KE; Nolte RT; Hattori K; Yoshinaga T; Kawasuji T; Underwood MR
    PLoS One; 2013; 8(10):e77448. PubMed ID: 24146996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic susceptibility of HIV-2 to raltegravir: integrase mutations Q148R and N155H confer raltegravir resistance.
    Smith RA; Raugi DN; Kiviat NB; Hawes SE; Mullins JI; Sow PS; Gottlieb GS;
    AIDS; 2011 Nov; 25(18):2235-41. PubMed ID: 21971360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.
    Fransen S; Gupta S; Danovich R; Hazuda D; Miller M; Witmer M; Petropoulos CJ; Huang W
    J Virol; 2009 Nov; 83(22):11440-6. PubMed ID: 19759152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.